Ultrahigh resolution profiles lead to more detailed serum peptidome signatures of pancreatic cancer

Translational Proteomics

Volumn 2, Issue 1, 2014, Pages 39-51

  Nicolardi, Simone ^a   Velstra, Berit ^a   Mertens, Bart J ^a   Bonsing, Bert ^a   Mesker, Wilma E ^a   Tollenaar, Rob A E M ^a   Deelder, André M ^a   Van Der Burgt, Yuri E M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

FTICR; Mass spectrometry; Pancreatic cancer; Proteomics; Serum protein profiling

Indexed keywords

BIOLOGICAL MARKER;

ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; JAUNDICE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION ION CYCLOTRON RESONANCE MASS SPECTROMETRY; PAIN; PANCREAS CANCER; PEPTIDOMICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SOLID PHASE EXTRACTION; WEIGHT REDUCTION;

EID: 84994472143     PISSN: 22129626     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trprot.2013.12.003     Document Type: Article

References (33)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: Cancer J Clin 2011, 61:69-90.
2. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011. CA: Cancer J Clin 2011, 61:212-236.
3. Wong T., Howes N., Threadgold J., Smart H.L., Lombard M.G., Gilmore I., et al. Molecular diagnosis of early pancreatic ductal adenocarcinoma in high-risk patients. Pancreatology 2001, 1:486-509.
4. Sener S.F., Fremgen A., Menck H.R., Winchester D.P. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999, 189:1-7.
5. Goonetilleke K.S., Siriwardena A.K. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007, 33:266-270.
6. Nilsson T., Mann M., Aebersold R., Yates J.R., Bairoch A., Bergeron J.J.M. Mass spectrometry in high-throughput proteomics: ready for the big time. Nat Methods 2010, 7:681-685.
7. Albrethsen J. The first decade of MALDI protein profiling: a lesson in translational biomarker research. J Proteomics 2011, 74:765-773.
8. de Noo M.E., Tollenaar R.A., Deelder A.M., Bouwman L.H. Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears. World J Gastroenterol 2006, 12:6594-6601.
9. Velstra B., van der Burgt Y.E., Mertens B.J., Mesker W.E., Deelder A.M., Tollenaar R.A. Improved classification of breast cancer peptide and protein profiles by combining two serum workup procedures. J Cancer Res Clin Oncol 2012, 138:1983-1992.
10. Callesen A.K., Vach W., Jørgensen P.E., Cold S., Mogensen O., Kruse T.A., et al. Reproducibility of mass spectrometry based protein profiles for diagnosis of breast cancer across clinical studies: a systematic review. J Proteome Res 2008, 7:1395-1402.
11. Beretta L. Proteomics from the clinical perspective: many hopes and much debate. Nat Methods 2007, 4:785-786.
12. Anderson N.G. Adventures in clinical chemistry and proteomics: a personal account. Clin Chem 2010, 56:154-160.
13. Kinsinger C.R., Apffel J., Baker M., Bian X., Borchers C.H., Bradshaw R., et al. Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam principles). Proteomics Clin Appl 2011, 5:580-589.
14. Callesen A.K., Christensen R.d., Madsen J.S., Vach W., Zapico E., Cold S., et al. Reproducibility of serum protein profiling by systematic assessment using solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 2008, 22:291-300.
15. Bladergroen M.R., Derks R.J.E., Nicolardi S., de Visser B., van Berloo S., van der Burgt Y.E.M., et al. Standardized and automated solid-phase extraction procedures for high-throughput proteomics of body fluids. J Proteomics 2012, 77:144-153.
16. Percy A., Chambers A., Yang J., Domanski D., Borchers C. Comparison of standard- and nano-flow liquid chromatography platforms for MRM-based quantitation of putative plasma biomarker proteins. Anal Bioanal Chem 2012, 404:1089-1101.
17. Nicolardi S., Dalebout H., Bladergroen M.R., Mesker W.E., Tollenaar R.A.E.M., Deelder A.M., et al. Identification of human serum peptides in Fourier transform ion cyclotron resonance precision profiles. Int J Proteomics 2012, 804036.
18. Villanueva J., Shaffer D.R., Philip J., Chaparro C.A., Erdjument-Bromage H., Olshen A.B., et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006, 116:271-284.
19. Velstra B., Bonsing B.A., Mertens B.J., van der Burgt Y.E.M., Huijbers A., Vasen H., et al. Detection of pancreatic cancer using serum protein profiling. HPB 2012.
20. Nicolardi S., Palmblad M., Dalebout H., Bladergroen M., Tollenaar R.A.E.M., Deelder A.M., et al. Quality control based on isotopic distributions for high-throughput MALDI-TOF and MALDI-FTICR serum peptide profiling. J Am Soc Mass Spectrom 2010, 21:1515-1525.
21. Marshall J., Jankowski A., Furesz S., Kireeva I., Barker L., Dombrovsky M., et al. Human serum proteins preseparated by electrophoresis or chromatography followed by tandem mass spectrometry. J Proteome Res 2004, 3:364-382.
22. Hagman C., Ramström M., Håkansson P., Bergquist J. Quantitative analysis of tryptic protein mixtures using electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. J Proteome Res 2004, 3:587-594.
23. Hertkorn N., Ruecker C., Meringer M., Gugisch R., Frommberger M., Perdue E.M., et al. High-precision frequency measurements: indispensable tools at the core of the molecular-level analysis of complex systems. Anal Bioanal Chem 2007, 389:1311-1327.
24. Marshall A.G., Hendrickson C.L., Jackson G.S. Fourier transform ion cyclotron resonance mass spectrometry: a primer. Mass Spectrom Rev 1998, 17:1-35.
25. Scigelova M., Hornshaw M., Giannakopulos A., Makarov A. Fourier transform mass spectrometry. Mol Cell Proteomics 2011, 10.
26. Nicolardi S., van der Burgt Y.E.M., Wuhrer M., Deelder A.M. Mapping O-glycosylation of apolipoprotein C-III in MALDI-FTICR protein profiles. Proteomics 2013, 13:992-1001.
27. Nicolardi S., Palmblad M., Hensbergen P.J., Tollenaar R.A.E.M., Deelder A.M., van der Burgt Y.E.M. Precision profiling and identification of human serum peptides using Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun Mass Spectrom 2011, 25:3457-3463.
28. Hortin G.L. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 2006, 52:1223-1237.
29. Tiss A., Smith C., Menon U., Jacobs I., Timms J.F., Cramer R. A well-characterised peak identification list of MALDI MS profile peaks for human blood serum. Proteomics 2010, 10:3388-3392.
30. Villanueva J., Philip J., Entenberg D., Chaparro C.A., Tanwar M.K., Holland E.C., et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 2004, 76:1560-1570.
31. Villanueva J., Philip J., Chaparro C.A., Li Y., Toledo-Crow R., DeNoyer L., et al. Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res 2005, 4:1060-1072.
32. Velstra B., Burgt Y., Mertens B., Mesker W., Deelder A.M., Tollenaar R. Improved classification of breast cancer peptide and protein profiles by combining two serum workup procedures. J Cancer Res Clin Oncol 2012, 138:1983-1992.
33. Nikolaev E.N., Jertz R., Grigoryev A., Baykut G. Fine structure in isotopic peak distributions measured using a dynamically harmonized Fourier transform ion cyclotron resonance cell at 7T. Anal Chem 2012, 84:2275-2283.